失代偿期肝硬化患者的乙型肝炎治疗。
Treatment of hepatitis B in decompensated liver cirrhosis.
作者信息
Guan Richard, Lui Hock Foong
机构信息
Mount Elizabeth Hospital and Medical Centre, Singapore 228510.
出版信息
Int J Hepatol. 2011;2011:918017. doi: 10.4061/2011/918017. Epub 2011 Jun 23.
Abstract
Chronic hepatitis B infection progresses from an asymptomatic persistently infected state to chronic hepatitis, cirrhosis, decompensated liver disease, and/or hepatocellular carcinoma. About 3% of patients with chronic hepatitis develop cirrhosis yearly, and about 5% of individuals with hepatitis B cirrhosis become decompensated annually. The outcome for patients with decompensated cirrhosis is bleak. Lamivudine, the first oral antiviral agent available for hepatitis B treatment is safe and effective and can improve or stabilize liver disease in patients with advanced cirrhosis and viraemia. Viral resistance restricts its prolonged use. Entecavir and tenofovir are newer agents with excellent resistance profile to date. These and some other antiviral agents are being investigated for optimal use in this rather challenging patient group.
摘要
慢性乙型肝炎感染可从无症状持续感染状态发展为慢性肝炎、肝硬化、失代偿性肝病和/或肝细胞癌。每年约3%的慢性肝炎患者会发展为肝硬化，每年约5%的乙型肝炎肝硬化患者会出现失代偿。失代偿性肝硬化患者的预后不佳。拉米夫定是首个可用于治疗乙型肝炎的口服抗病毒药物，安全有效，可改善或稳定晚期肝硬化和病毒血症患者的肝病状况。病毒耐药性限制了其长期使用。恩替卡韦和替诺福韦是目前耐药性良好的新型药物。正在对这些药物及其他一些抗病毒药物进行研究，以确定在这一颇具挑战性的患者群体中的最佳用药方案。
相似文献
1
Treatment of hepatitis B in decompensated liver cirrhosis.失代偿期肝硬化患者的乙型肝炎治疗。
Int J Hepatol. 2011;2011:918017. doi: 10.4061/2011/918017. Epub 2011 Jun 23.
2
Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease.恩替卡韦：治疗肝功能失代偿的慢性乙型肝炎患者的综述。
Drugs. 2011 Dec 24;71(18):2511-29. doi: 10.2165/11208510-000000000-00000.
3
Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.拉米夫定、恩替卡韦和替诺福韦治疗乙型肝炎病毒相关肝硬化的长期疗效和安全性。
Clin Gastroenterol Hepatol. 2013 Jan;11(1):88-94. doi: 10.1016/j.cgh.2012.10.003. Epub 2012 Oct 9.
4
Management of patients with decompensated HBV cirrhosis.失代偿期乙肝肝硬化患者的管理
Semin Liver Dis. 2003 Feb;23(1):89-100. doi: 10.1055/s-2003-37591.
5
Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis.恩替卡韦治疗乙型肝炎病毒相关失代偿期肝硬化患者。
Expert Opin Pharmacother. 2013 Jul;14(10):1363-9. doi: 10.1517/14656566.2013.786701. Epub 2013 Apr 4.
6
Management of viral hepatitis B.乙型病毒性肝炎的管理
J Gastroenterol Hepatol. 2002 Feb;17 Suppl:S125-45. doi: 10.1046/j.1440-1746.17.s1.3.x.
7
Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.替诺福韦和恩替卡韦在乙型肝炎病毒相关性肝硬化中的长期使用。
Indian J Gastroenterol. 2015 Jul;34(4):286-91. doi: 10.1007/s12664-015-0576-1. Epub 2015 Aug 6.
8
Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.抗病毒治疗应答对慢性乙型肝炎病毒感染伴失代偿期肝硬化患者短期和长期结局的影响。
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1954-1963.e3. doi: 10.1016/j.cgh.2018.04.063. Epub 2018 May 9.
9
Lamivudine treatment in patients with chronic hepatitis B and cirrhosis.
Expert Opin Pharmacother. 2006 Sep;7(13):1835-43. doi: 10.1517/14656566.7.13.1835.
10
Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy.乙型肝炎病毒相关失代偿期肝硬化：抗病毒治疗的获益。
J Hepatol. 2012 Aug;57(2):442-50. doi: 10.1016/j.jhep.2012.02.033. Epub 2012 Apr 12.
引用本文的文献
1
Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy.在中国新的按采购量计价政策下，替诺福韦艾拉酚胺在慢性乙型肝炎治疗的成本效益方面优于富马酸替诺福韦二吡呋酯和恩替卡韦。
PLoS One. 2025 Jul 11;20(7):e0327298. doi: 10.1371/journal.pone.0327298. eCollection 2025.
2
Antioxidant interventions reduced cytokine-induced pyroptosis of peripheral MAIT cells in patients with HBV-related cirrhosis.抗氧化干预可减少乙型肝炎病毒相关肝硬化患者外周黏膜相关恒定T细胞（MAIT细胞）的细胞因子诱导的焦亡。
Hepatol Commun. 2025 May 16;9(6). doi: 10.1097/HC9.0000000000000714. eCollection 2025 Jun 1.
3
Recovery of cardiac electrophysiological alterations by heart rate complexity based on multiscale entropy following liver transplantation.基于多尺度熵的心率复杂度对肝移植后心脏电生理改变的恢复作用。
Sci Rep. 2024 Mar 29;14(1):7467. doi: 10.1038/s41598-024-58191-8.
4
Identification of miR-4793-3p as a potential biomarker for bacterial infection in patients with hepatitis B virus-related liver cirrhosis: A pilot study.鉴定miR-4793-3p作为乙型肝炎病毒相关肝硬化患者细菌感染的潜在生物标志物：一项初步研究。
Exp Ther Med. 2021 Feb;21(2):120. doi: 10.3892/etm.2020.9552. Epub 2020 Dec 3.
5
Role of alcohol in pathogenesis of hepatitis B virus infection.酒精在乙型肝炎病毒感染发病机制中的作用。
World J Gastroenterol. 2020 Mar 7;26(9):883-903. doi: 10.3748/wjg.v26.i9.883.
6
Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention.失代偿期肝硬化门诊患者的药物相关问题：预防危害的机会
Hepatol Commun. 2019 Mar 18;3(5):620-631. doi: 10.1002/hep4.1334. eCollection 2019 May.
7
Prognostic significance of vitamin D receptor (VDR) gene polymorphisms in liver cirrhosis.维生素 D 受体（VDR）基因多态性与肝硬化的预后意义。
Sci Rep. 2018 Sep 14;8(1):14065. doi: 10.1038/s41598-018-32482-3.
8
A sonographic Doppler study of the hepatic vein, portal vein and hepatic artery in liver cirrhosis: Correlation of hepatic hemodynamics with clinical Child Pugh score in Singapore.肝硬化患者肝静脉、门静脉及肝动脉的超声多普勒研究：新加坡肝血流动力学与临床Child-Pugh评分的相关性
Ultrasound. 2017 Nov;25(4):213-221. doi: 10.1177/1742271X17721265. Epub 2017 Aug 3.
9
Novelties in the pathophysiology and management of portal hypertension: new treatments on the horizon.门静脉高压症病理生理学和治疗学的新进展：新的治疗方法即将出现。
Hepatol Int. 2018 Feb;12(Suppl 1):112-121. doi: 10.1007/s12072-017-9806-1. Epub 2017 Jul 11.
10
Aberrant Resting-State Functional Connectivity Density in Patients with Hepatitis B Virus-Related Cirrhosis.乙型肝炎病毒相关性肝硬化患者异常的静息态功能连接密度
Biomed Res Int. 2016;2016:4168512. doi: 10.1155/2016/4168512. Epub 2016 Jun 14.
本文引用的文献
1
Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.恩替卡韦与阿德福韦酯治疗失代偿期慢性乙型肝炎患者的疗效和安全性：一项随机、开放标签研究。
Hepatology. 2011 Jul;54(1):91-100. doi: 10.1002/hep.24361.
2
Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.恩替卡韦治疗乙型肝炎病毒相关失代偿期肝硬化患者的疗效。
J Hepatol. 2010 Feb;52(2):176-82. doi: 10.1016/j.jhep.2009.11.007. Epub 2009 Dec 16.
3
Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function.在肝功能受损的慢性乙型肝炎患者中，使用恩替卡韦治疗期间出现严重乳酸酸中毒。
Hepatology. 2009 Dec;50(6):2001-6. doi: 10.1002/hep.23346.
4
Chronic hepatitis B: update 2009.慢性乙型肝炎：2009年更新
Hepatology. 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190.
5
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.亚太地区慢性乙型肝炎管理共识声明：2008 年更新版。
Hepatol Int. 2008 Sep;2(3):263-83. doi: 10.1007/s12072-008-9080-3. Epub 2008 May 10.
6
Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.长期监测显示，初治患者在接受5年恩替卡韦治疗期间，对该药物产生乙肝病毒耐药的情况罕见。
Hepatology. 2009 May;49(5):1503-14. doi: 10.1002/hep.22841.
7
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.慢性乙型肝炎e抗原阳性患者早期乙肝病毒DNA的降低：恩替卡韦与阿德福韦的一项随机国际研究
Hepatology. 2009 Jan;49(1):72-9. doi: 10.1002/hep.22658.
8
EASL Clinical Practice Guidelines: management of chronic hepatitis B.欧洲肝脏研究学会临床实践指南：慢性乙型肝炎的管理
J Hepatol. 2009 Feb;50(2):227-42. doi: 10.1016/j.jhep.2008.10.001. Epub 2008 Oct 29.
9
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis.一项关于用阿德福韦酯替代乙肝免疫球蛋白联合拉米夫定作为肝移植后乙肝预防措施的随机研究。
Hepatology. 2008 Nov;48(5):1460-6. doi: 10.1002/hep.22524.
10
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update.美国慢性乙型肝炎病毒感染管理的治疗算法：2008年更新版
Clin Gastroenterol Hepatol. 2008 Dec;6(12):1315-41; quiz 1286. doi: 10.1016/j.cgh.2008.08.021. Epub 2008 Aug 23.
Zotero 插件